Berkane Nadia, Braneti Roland, Streuli Isabelle, Martinez De Tejada Begoña, Dubuisson Jean
Service d'obstétrique, Département de la femme, de l'enfant et de l'adolescent, HUG, 1211 Genève 14.
Unité de médecine de la reproduction, Département de la femme, de l'enfant et de l'adolescent, HUG, 1211 Genève 14.
Rev Med Suisse. 2020 Jan 15;16(676-7):42-46.
Uterine transplant is a novel treatment option for women with absolute uterine infertility. Sixty uterine transplants have been performed worldwide to date. The first live birth happened in 2014 and since then 20 children have been born after this procedure. The procedure has several challenges: The donor is usually a woman alive. Surgery is long and complex for both the donor and the recipient, with a high risk of complications. Embryos have to be obtained through IVF. Pregnancies are at high risk for complications and require cesarean delivery, and transplant is temporary (the transplanted uterus is removed after pregnancy in order to allow discontinuation of immunosuppressive therapy). Uterine transplant is a new hope for women with absolute uterine infertility but a high-risk experimental procedure for the donor, the recipient and the newborns and raises major ethical questions.
子宫移植是治疗绝对子宫性不孕女性的一种新的治疗选择。迄今为止，全球已进行了60例子宫移植手术。首例活产发生在2014年，自那时起，已有20名儿童通过该手术出生。该手术存在诸多挑战：供体通常为在世女性。对供体和受体而言，手术时间长且复杂，并发症风险高。胚胎必须通过体外受精获得。妊娠并发症风险高，需要剖宫产，且移植是临时性的（妊娠后切除移植的子宫，以便停止免疫抑制治疗）。子宫移植对于绝对子宫性不孕的女性来说是新的希望，但对供体、受体和新生儿而言是高风险的实验性手术，还引发了重大的伦理问题。
